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Abstract
Introduction: Chronic low-grade inflammation is a significant factor in the development of obesity associated diabetes.
This is supported by recent studies suggesting endotoxin, derived from gut flora, may be key to the development of
inflammation by stimulating the secretion of an adverse cytokine profile from adipose tissue.
Aims: The study investigated the relationship between endotoxin and various metabolic parameters of diabetic patients
to determine if anti-diabetic therapies exerted a significant effect on endotoxin levels and adipocytokine profiles.
Methods: Fasting blood samples were collected from consenting Saudi Arabian patients (BMI: 30.2 ± (SD)5.6 kg/m2, n
= 413), consisting of non-diabetics (ND: n = 67) and T2DM subjects (n = 346). The diabetics were divided into 5
subgroups based on their 1 year treatment regimes: diet-controlled (n = 36), metformin (n = 141), rosiglitazone (RSG:
n = 22), a combined fixed dose of metformin/rosiglitazone (met/RSG n = 100) and insulin (n = 47). Lipid profiles, fasting
plasma glucose, insulin, adiponectin, resistin, TNF-α, leptin, C-reactive protein (CRP) and endotoxin concentrations
were determined.
Results: Regression analyses revealed significant correlations between endotoxin levels and triglycerides (R2 = 0.42; p <
0.0001); total cholesterol (R2 = 0.10; p < 0.001), glucose (R2 = 0.076; p < 0.001) and insulin (R2 = 0.032; p < 0.001) in
T2DM subjects. Endotoxin showed a strong inverse correlation with HDL-cholesterol (R2 = 0.055; p < 0.001). Further,
endotoxin levels were elevated in all of the treated diabetic subgroups compared with ND, with the RSG treated
diabetics showing significantly lower endotoxin levels than all of the other treatment groups (ND: 4.2 ± 1.7 EU/ml, RSG:
5.6 ± 2.2 EU/ml). Both the met/RSG and RSG treated groups had significantly higher adiponectin levels than all the other
groups, with the RSG group expressing the highest levels overall.
Conclusion: We conclude that sub-clinical inflammation in T2DM may, in part, be mediated by circulating endotoxin.
Furthermore, that whilst the endotoxin and adipocytokine profiles of diabetic patients treated with different therapies
were comparable, the RSG group demonstrated significant differences in both adiponectin and endotoxin levels. We
confirm an association between endotoxin and serum insulin and triglycerides and an inverse relationship with HDL.
Lower endotoxin and higher adiponectin in the groups treated with RSG may be related and indicate another mechanism
for the effect of RSG on insulin sensitivity.
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In recent years, obesity, insulin resistance, as well as many
of the features that comprise the metabolic syndrome, are
associated with a low-grade, systemic, inflammatory con-
dition [1,2]. In particular, the mediation of this sub-clini-
cal inflammation in the pathogenesis of Type 2 Diabetes
Mellitus (T2DM) is proposed to arise through increasing
adiposity [3,4]; with adipose tissue representing a site of
an acute phase response [5,6] through the production of
known pro-inflammatory adipocytokines such as leptin,
tumor necrosis factor (TNF-α) and interleukin (IL-6),
amongst others [7-9]. Specifically, adipocytokines appear
to have a duality of function, simultaneously mediating
inflammation and insulin resistance through their effects
on insulin action. Therefore, adipocytokines may func-
tion as a consequence of the cross-link proposed between
metabolic and inflammatory pathways in adipocytes and
immune cells [10-12].
Current therapies utilized in the treatment of T2DM
include metformin and the thiazolidinediones (TZDs).
These agents have principally been evaluated on the basis
of their beneficial effects on glucose metabolism, due to
their insulin enhancing properties. Metformin and rosigl-
itazone (RSG) are widely accepted first-line anti-diabetic
drug therapies, whether taken as a monotherapy or in
combination [13], and are considered effective with low
incidence of hypoglycemia [14]. In addition to their
effects on glucose homeostasis, metformin, itself, is
known to reduce leptin, with resultant effects on inflam-
matory status and satiety [15]. Furthermore, the TZDs
have previously been shown to have immunomodulatory
effects [16]; reducing inflammation in both in-vitro and
in-vivo models [17-19]. These findings highlight alterna-
tive pathways through which drug therapies are able to
counteract the progressive nature of metabolic disease and
their potential dual action on reducing obesity mediated
T2DM.
Whilst metformin and the TZDs appear to offer dual func-
tionality in insulin resistance and inflammation, the ini-
tial mediator for such an inflammatory insult is less well
understood. One source of sub-clinical inflammation in
patients with T2DM and coronary heart disease may arise
through commensal bacteria derived from the gut,
referred to as endotoxin [20]. Endotoxin is derived from
lipopolysaccharide (LPS), which represents cell wall frag-
ments of gram negative bacteria. Previous studies have
demonstrated that subjects with obesity and T2DM have
elevated circulating levels of endotoxin compared with
non-diabetics (ND), which has been implicated in
increased inflammatory risk [21]. Further support for this
concept has arisen in subsequent studies where serum
endotoxin levels are significantly higher in ob/ob and db/db
mice compared with their normal weight counterparts
[22]. Studies suggest elevated endotoxin levels may arise
as a result of obesity related hyperinsulinemia; hence low-
grade endotoxinemia may be caused by the effect of insu-
lin on intestinal motility and/or intestinal permeability.
In support of this theory, murine studies analyzing the
gastrointestinal tract (GIT) of ob/ob and db/db mice identi-
fied pathological changes in the GIT cells. The findings
indicated that insulin may act directly on the GIT to affect
gut permeability and potentially increase endotoxin
absorption [22]. Elevated circulating levels of endotoxin
may then initiate an inflammatory response within adi-
pose tissue, via innate immunity, in conjunction with the
liver, as the latter is the primary site of endotoxin clear-
ance under normal physiological circumstances [6,22].
This mechanism may, therefore, explain the state of sub-
clinical inflammation often present in obese and type 2
diabetic subjects [2].
Whilst limited data have been presented on the increase of
endotoxin in pathological conditions such as obesity and
diabetes, no data, as yet, have evaluated the influence of
insulin sensitizers, in combination, on inflammatory risk
posed by circulating endotoxin. Whilst there is a large
quantity of data available on obesity and T2DM in rela-
tion to the Western world, less information exists regard-
ing populations in the transitional state. In particular,
Saudi Arabia has experienced a rapid increase in wealth
over a relatively short period of time as a consequence of
the financial gains rendered by the oil industry, paralleled
with swift industrialization and urbanization [23]. As a
result, the burden of disease in Saudi Arabia is high. The
Obesity Taskforce worldwide projections for 2030 predict
that the incidence of diabetes will rise by 32% in Europe,
72% in the USA but will increase by a massive 164% in
the Middle East [24,25]. As such, it is clear we need to
have a fundamental understanding of their risk of inflam-
mation and how insulin sensitizers, along with other ther-
apies, may reduce such a risk.
Therefore, the aims of this present study were to establish
any associations between endotoxin and insulin, glucose,
lipid profiles and pro-inflammatory cytokines in a Saudi
Arabian cohort consisting of obese, ND subjects and
obese, T2DM patients on various anti-diabetic therapies.
Furthermore, the study aimed to examine the influence of
diet, metformin, RSG, met/RSG as well as insulin on
endotoxin levels and its' association with inflammation.
Ultimately, this study will evaluate whether alterations in
endotoxin, coupled with altered metabolic profile, in type
2 diabetics might further explain the observed improve-
ment in the clinical profiles of patients treated with these
therapies. This present study, in combination with our
previous findings, may therefore help determine endo-
toxin as a novel biomarker of T2DM and diabetic risk and
hence proffer a new target for the treatment or prevention
of diabetes.Page 2 of 10
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This single-centre, prospective and cross-sectional study
was carried out at the Diabetes Center of King Abdul-aziz
University Hospital in Riyadh, Kingdom of Saudi Arabia.
The study protocol was approved by the institutional
review board and was conducted in accordance with the
guidelines set by the College of Medicine and Research
Center of King Saud University, Riyadh, Kingdom of
Saudi Arabia ethics committee. All patients submitted
written and informed consent prior to inclusion.
Subjects
The study consisted of a total of 413 out-patients (male:
203; female: 210) age 20–80. Furthermore, 346 subjects
were known type 2 diabetics, while the remaining 67 were
ND, closely matched for BMI.
Inclusion criteria for the diabetics (prior diagnosis) were
determined in the first screening visit and included HBA1c
6–11%, fasting plasma glucose 7.0–14.0 mmol/l; BMI
22–40 kg/m2; without co-existing diabetic complications,
i.e. diabetic retinopathy, nephropathy, etc. Subjects must
have received treatment (diet controlled, metformin, RSG,
met/RSG or insulin) for at least one year. ND subjects had
normal fasting plasma glucose (<5.6 mmol/l); HBA1c lev-
els (4–6%) and were not taking any medications prior to
commencement of research. Patients were excluded if
they had poorly controlled diabetes with co-existing com-
plications, smoking history, history of coronary heart dis-
ease and any unstable medical condition/s that would
require immediate attention.
All subjects underwent a complete physical examination,
which included an electrocardiogram prior to enrolment.
Qualified patients were then stratified into 6 groups on
the basis of their hypoglycemic therapies (diet-controlled
(n = 36), metformin (n = 141), RSG (n = 22), met/RSG (n
= 100) and insulin (n = 47)), in addition to the ND group
(n = 67). Following the findings of the initial study, a sub-
group of diabetic subjects (n = 11, BMI 31.7 ± 6.42 kg/m2)
were treated with RSG for a period of 6 months (Post RSG:
BMI 30.9 ± 4.42 kg/m2), in order to determine the specific
effect of RSG treatment on endotoxin levels.
In vivo Assessment of the Biochemical profile, 
Adipocytokines and Endotoxin Levels
On the assigned date, fasting blood samples were col-
lected from participating subjects and lipid profiles and
fasting plasma glucose determined using routine labora-
tory methods. Adipocytokine levels were also assessed
using various sandwich enzyme-linked immunosorbent
assays (ELISAs). These included adiponectin (Linco Ltd,
USA; intra-assay variability 7.0%, interassay variability
8.4%), resistin (RnD Systems Ltd, UK; intra- 4.0%, inte-
rassay variability 7.7%), TNF-α (RnD Systems Ltd, UK;
intra- 5.2%, interassay variability 7.4%), leptin (intra-
3.3%, interassay variability 5.4%) and C-reactive protein
(CRP, Immunodiagnoztik AG, Germany; intra- 6%, inte-
rassay variability 11.6%). Insulin was analyzed via a solid
phase enzyme amplified sensitivity immunoassay
(Medgenix INS-ELISA, Biosource, Belgium). Lastly, endo-
toxin concentration was measured using a chromogenic
kinetic limulus amebocyte assay (LAL assay, BioWhitaker,
Walkersville MD), which had been validated, previously
[21].
Statistical Analyses
Data were analyzed using the Statistical Package SPSS for
Windows, version 11.5. Data were expressed as mean ±
standard deviation and mean (interquartile range) if not
normally distributed. Groups were compared using
ANOVA with Bonferroni adjustments for inter group
comparisons. Simple and partial correlation coefficients
between the variables were determined and multiple
regression analysis was carried out to determine variables
of interest. Triglycerides, insulin, leptin, adiponectin,
CRP, resistin and endotoxin were logarithmically trans-
formed to normalize data before correlations and statisti-
cal analyses were performed.
Results
Metabolic and Clinical Characteristics
Baseline characteristics
Table 1 shows the clinical and metabolic characteristics of
the 6 groups analyzed in this study. The mean systolic
blood pressures of the groups were similar, with the diet
and RSG treated group having the lowest mean systolic
blood pressures (111.6 ± 22.9 mmHg and 114.1 ± 28.7
mmHg, respectively) and the met/RSG group (128.4 ±
23.6 mmHg, p < 0.05) the highest. The mean diastolic
blood pressures of the ND (84.1 ± 14.6 mmHg) and met/
RSG treated groups (84.6 ± 13.0 mmHg) were signifi-
cantly lower than the insulin treated group (96.0 ± 15.5
mmHg, p < 0.05). Waist to hip ratios (WHR) were similar
across all groups with the insulin treated group showing
the highest WHR (1.4 ± 0.4), that differed significantly
from the ND and the met/RSG treated groups (ND: 1.1 ±
0.2; met/RSG: 1.1 ± 0.3, p < 0.05). As would be expected,
the ND group had significantly lower fasting plasma glu-
cose levels compared with the other 5 groups. The groups
were comparable in terms of lipid profile, although only
the triglyceride levels in the diet and RSG treated groups
(diet: 1.6(0.9–2.3) mmol/l; RSG: 1.6(0.8–2.3) mmol/l, p
< 0.05) did not differ significantly from the ND group
(1.4(1.0–1.9) mmol/l, table 1).
Associations Between Endotoxin levels and Metabolic Factors in 
Subjects with T2DM
Regression analyses revealed a significant correlation
between endotoxin levels and triglycerides (R2 = 0.42; p <Page 3 of 10
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cholesterol values (R2 = 0.055; p < 0.001, figure 1b) and a
significant correlation between total cholesterol levels (R2
= 0.10; p < 0.001, figure 1c) in the diabetic cohort. The
correlation between endotoxin levels and triglycerides, as
well as cholesterol, remained even in the absence of dia-
betes (R2 = 0.192; p < 0.0001, figure 2a; R2 = 0.163; p <
0.001, figure 2c). Lastly we found a significant association
between endotoxin levels and insulin (R2 = 0.032; p <
0.001, figure 3a) and glucose (R2 = 0.076; p < 0.001, figure
3b) in the type 2 diabetics, which was not present in the
ND group (figure 3c and 3d). The rest of the analyses were
not significant.
Circulating Endotoxin Levels in ND and Treated T2DM Subjects
Serum endotoxin levels were lowest in the ND group
(4.2(3.1–5.1) EU/ml, table 1), with the insulin treated
cohort exhibiting the highest levels (9.2(6.6–10.7) EU/
ml, table 1). Only the RSG treated group showed signifi-
cantly lower endotoxin levels than all of the other anti-
diabetic therapies (RSG: 5.65(4.2–6.1) EU/ml, table 1).
Compared with baseline values, endotoxin levels showed
Table 1: Clinical and Metabolic Characteristics of Subjects
Variables Non-Diabetic Diet Insulin Metformin Rosiglitazone Met/RSG
Age (years) 44.1 ± 9.9§‡*†** 48.3 ± 9.1‡*** 55.6 ± 11.4 53.0 ± 10.5 52.3 ± 9.5 52.5 ± 9.0
BMI (kg/m2) 30.0 ± 5.2 29.6 ± 5.8 29.0 ± 6.2 32.0 ± 5.8 29.6 ± 5.8 31.0 ± 5.3
Systolic (mmHg) 117.3 ± 20.0 111.6 ± 22.9*** 115.7 ± 24.9** 123.8 ± 23.5 114.1 ± 28.7** 128.4 ± 23.6
Diastolic (mmHg) 84.1 ± 14.6‡* 88.2 ± 14.9‡ 96.0 ± 15.5*** 90.3 ± 14.3** 90.9 ± 16.3 84.6 ± 13.0
WHR 1.1 ± 0.2§‡† 1.3 ± 0.4** 1.4 ± 0.4** 1.3 ± 0.4** 1.3 ± 0.3** 1.1 ± 0.3
Glucose (mmol/l) 5.5 ± 1.5§‡*†** 7.1 ± 2.8‡*** 9.5 ± 3.8 9.6 ± 3.4 8.4 ± 1.9 9.4 ± 3.9
Insulin (ng/ml)# 20.1(10.9–23.0)‡ 19.1(10.7–24.6)‡ 29.9(21.2–36.6)*** 20.7(10.9–27.3) 21.5(11.8–20.5) 17.1(7.6–17.2)
LDL-C (mmol/l) 3.2 ± 0.9§* 2.7 ± 0.8 3.0 ± 1.0 2.8 ± 0.8 2.8 ± 0.7 3.0 ± 1.4
HDL-C (mmol/l) 1.2 ± 0.4 1.3 ± 0.7 1.1 ± 0.4 1.1 ± 0.4 1.0 ± 0.4 1.2 ± 0.5
TC (mmol/l) 5.0 ± 1.0 4.7 ± 1.0 4.9 ± 1.1 4.8 ± 1.0 4.5 ± 0.9** 5.1 ± 1.2
TG (mmol/l)# 1.4 (1.0–1.9)*** 1.6(0.9–2.3)*** 1.8(1.2–2.4) 2.1(1.3–2.4) 1.6(0.8–2.3) 2.2(1.3–2.5)
Leptin (ng/ml)# 31.0(14.6–42.2)§*†** 18.2(5.8–23.4)‡ 27.5(9.8–39.3)†** 22.5(9.6–29.6)** 16.2(5.2–19.8) 18.6(4.9–21.7)
Adiponectin (μg/ml)# 8.5(5.1–1.0) †** 8.6 (5.7–10.4)†** 10.4 (5.3–13.2)†** 9.1(6.0–11.3)†** 16.1(10.2–20.1) 14.3(8.9–16.1)
CRP(μg/ml)# 4.2(1.1–5.2) 3.8 (2.5–4.9)‡ 6.3 (1.5–6.5)** 4.6(1.3–4.7) 3.7(0.8–4.6) 3.6(1.0–3.9)
Resistin (ng/ml)# 15.6(10.7–19.8)† 15.0(14.5–17.9)† 17.6(10.5–18.4)†** 16.1(11.3–18.1)†** 11.9(8.0–13.7)** 14.2(10.4–16.7)
TNF-α (pg/ml)# 5.4(3.4–7.3)*** 4.7(2.9–6.2) 5.4 (2.7–7.4)* 4.2(2.8–5.3)† 5.9(4.3–6.8)** 4.5(3.3–5.6)
Endotoxin(EU/ml)# 4.2(3.1–5.1)§‡*†** 7.9(5.7–10.0)† 9.2 (6.6–10.7)*†** 7.5(4.6–8.7)† 5.6 (4.2–6.1)** 7.4 (4.8–9.6)
Clinical characteristics for non-diabetic (ND) and T2DM subjects on anti-diabetic therapies. Variables marked with # were log transformed prior to 
statistical analysis. Hence data are presented as mean ± SD unless log transformed (#) in which case they are presented as mean (interquartile 
range). Significance was set at p < 0.05. Therefore §denotes a significant difference in the mean values when compared with diet; ‡ denotes 
significance when compared with insulin; *denotes significance when compared with metformin; † denotes significance compared with RSG; ** 
denotes significance when compared with met/RSG.Page 4 of 10
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Correlations between log fasting endotoxin (EU/ml) 
and a) log triglycerides (mmol/l), b) HDL (mmol/l) 
and c) cholesterol (mmol/l) in the whole diabetic 
cohort. The lines of best fit are also shown: a) R2 = 0.42, p < 
0.0001, b) R2 = 0.055, p < 0.001, c) R2 = 0.1, p < 0.001).
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Cardiovascular Diabetology 2009, 8:20 http://www.cardiab.com/content/8/1/20a 13.5% decrease post treatment with RSG (Figure 4, p <
0.05).
Circulating Adipocytokine Levels
With regard to adipocytokines, the leptin levels of the ND
group (31.0(14.6–42.2) ng/ml) were significantly higher
compared with the treated type 2 diabetic subgroups
(table 1). Adiponectin levels in the RSG (16.1(10.2–20.1)
μg/ml) and met/RSG (14.3(8.9–16.1) μg/ml) treated
groups were significantly higher than all the other groups,
with the RSG group showing almost a two fold increase in
adiponectin levels compared with the ND (8.5(5.1–10.0)
μg/ml, table 1). The mean resistin levels of the groups
were comparable, except for the RSG group which showed
the lowest resistin levels overall (11.9(8.0–13.7)ng/ml, p
< 0.05, table 1). CRP levels were highest in the insulin
Correlations between log endotoxin (EU/ml) and a) log fasting insulin (ng/ml) and b) glucose (mmol/l) in the whole diabetic cohortFigu e 3
Correlations between log endotoxin (EU/ml) and a) log fasting insulin (ng/ml) and b) glucose (mmol/l) in the 
whole diabetic cohort. The lines of best fit are also shown: a) R2 = 0.032, p < 0.001, b) R2 = 0.076, p < 0.001. Correlations 
between log endotoxin (EU/ml) and c) log fasting insulin (ng/ml) and d) glucose (mmol/l) in the non-diabetic (ND) group. The 
lines of best fit are also shown: c) R2 = 0.025, NS; d) R2 = 0.009, NS.
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whilst TNF-α levels were significantly higher in the RSG
treated group (5.9(4.3–6.8) pg/ml, p < 0.05, table 1).
Discussion
Recent studies have implicated a role for adipose tissue as
a site of systemic inflammation, thus providing a direct
link between obesity and the associated state of chronic
sub-clinical inflammation [2]. One principal source for
inflammatory risk may occur via the gastrointestinal tract
(GIT), as previous studies have determined that endo-
toxin can activate the innate immune response within adi-
pose tissue [16,21,22,26,27]. Such studies signify a
potential role for gut flora related induction of innate
immunity and circulating endotoxin in the pathogenesis
of obesity induced T2DM.
The findings from this study have highlighted that sub-
jects with T2DM had significantly elevated levels of endo-
toxin compared with BMI matched ND subjects. Hence,
these studies have affirmed previous findings in Cauca-
sian populations whilst increasing the studied subjects'
numbers four fold [21]. Our findings also demonstrated
that insulin treated subjects exhibited the highest circulat-
ing endotoxin levels of all the cohorts examined; addi-
tionally, both insulin and glucose were shown to correlate
significantly with endotoxin levels in the diabetic cohort
but not in the control group. As such, our current and pre-
vious data have highlighted an association between insu-
lin and endotoxin, suggesting a mechanism that
hyperinsulinemia/insulin resistance may lead to
increased absorption of endotoxin through the GIT
[22,28]. Whilst the findings of the present study support
the endotoxin/gut absorption hypothesis, it has not deter-
mined a causal effect and further studies would be
required to examine this theory. Therefore, endotoxin
may act as an inflammatory mediator in T2DM [21,22].
However our understanding of the relationship between
glucose and endotoxin is less clear, as previous studies
show no correlation between glucose levels and endo-
toxin [21], with Pederson and colleagues observing only a
moderate increase in glucose levels when subjects under-
went endotoxin infusion [29]. Conversely, severe human
sepsis is known to instigate a hypermetabolic stress
response, which includes hyperglycemia and impaired
glucose tolerance [30]. Studies in T2DM patients have
demonstrated that elevated glucose levels interfere with
macrophage function, suppressing the bactericidal capac-
ity of leukocytes [30], whilst murine studies have shown
elevated glucose levels cause adverse effects on jejunum
motility [31]. As such, hyperglycemia may make patients
more susceptible to further infection – as observed in
T2DM – as well as potentiating endotoxin absorption
through inhibition of gut motility. Although patients with
septic shock have considerably higher endotoxin levels
(10 – 50 fold) than type 2 diabetics [32], subjects with cir-
rhosis are comparable with obese and T2DM subjects
[33]. Therefore an association between glucose and endo-
toxin would suggest a role for endotoxin as an inflamma-
tory mediator [34]. Our current findings have identified a
clear, positive correlation between endotoxin and glucose
serum levels [21]. The apparent discrepancies between our
study and previous findings may have arisen due to the
large size of the cohort we examined. Therefore the rela-
tionship between endotoxin and glucose should be inves-
tigated through subsequent studies to corroborate our
findings.
The strong positive correlation identified between endo-
toxin and triglyceride levels is also of interest, noted in
both the T2DM subjects and ND group. It is well estab-
lished that subjects with obesity and T2DM have high
serum triglyceride and low HDL [35,36]. Studies have
indicated that HDL has a protective role against inflam-
mation and the effects of endotoxin [37,38]. Low levels of
HDL are associated with low levels of sCD14 [39], which
corresponds with data showing that LPS binds to HDL in
the presence of sCD14 and LPS binding protein (LBP)
[40-42], and enzymes involved in the presentation of LPS
to sCD14. This would imply that HDL is potentially
involved in the immunological response to LPS. In con-
trast, serum triglyceride levels are directly stimulated by
LPS [43] and are correlated with sCD14 [44]. Further-
more, it may act as a carrier of bacterial antigens and also
facilitate their clearance [45,46]. These findings would
have obvious implications in obese, T2DM patients.
Upon comparison of the different treatment regimes, only
the RSG group showed circulating endotoxin levels signif-
The mean levels of endotoxin (EU/ml) in sera from T2DM patients, pr  and post RSG treatment (  = 11, p < 0.05*)Figur  4
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The insulin treated cohort showed the highest circulating
levels of endotoxin, which advocates the theory that insu-
lin may promote increased endotoxin absorption from
the GIT [22]. Furthermore, all of the cohorts on anti-dia-
betic drug treatments, metformin, RSG and met/RSG,
showed significantly lower levels of endotoxin than insu-
lin – with the RSG treated group exhibiting the most dra-
matic decrease. Upon further analysis of pre and post RSG
treated T2DM subjects, there was a 13.5% decrease in
endotoxin levels over a 6 month period. These results con-
firm previous studies to show that RSG significantly
reduces endotoxin in T2DM patients [21], whilst also
indicating that RSG has a more significant effect on endo-
toxin levels than other anti-diabetic therapies. Therefore,
these findings may explain some of the anti-inflammatory
properties of the TZDs.
In addition, RSG and met/RSG treated subjects both
resulted in elevated adiponectin levels that, whilst compa-
rable to one another, were significantly higher than all the
other treated groups, including the ND group. These data
affirm findings by Rosenstock and colleagues and support
their suggestion that the observed increase in adiponectin
is due to RSG, as the TZDs have been shown to consist-
ently increase circulating adiponectin [47].
Assessment of other adipocytokines showed that leptin
levels were highest amongst the ND group and did not
correlate with endotoxin in all groups. However, to date,
the findings regarding leptin are conflicting. Patients with
sepsis are known to have elevated levels of leptin [48], yet
several studies have failed to demonstrate an increase in
leptin with endotoxin infusion [49,50], whilst studies in
mice and hamsters show increased leptin at the serum and
mRNA level with endotoxin administration [51,52]. Such
differences may have arisen from methodological reasons,
as our study measured the relationship between leptin
and endogenous endotoxin serum levels, as opposed to
the effects on leptin as a result of exogenous endotoxin
administration. Furthermore, within this study, the dia-
betic drugs may have decreased leptin concentration,
altering the determined findings [15,53].
In summary, both ND and diabetic subjects showed sig-
nificant associations with endotoxin and triglycerides and
total cholesterol. T2DM subjects demonstrated an inverse
correlation between endotoxin and HDL-cholesterol and
positive correlations between endotoxin and glucose and
endotoxin and insulin. As such, endotoxin may mediate
various metabolic changes in people with T2DM in
response to an increasing insulin resistant state, which is
also consistent with chronic systemic low-grade inflam-
mation. Our data suggest that the sub-clinical inflamma-
tion observed in T2DM patients may, in part, be derived
from commensal bacteria [54]. Whilst clinical treatment
of T2DM implies that RSG has the most favorable effect
on overall endotoxin reduction and adipocytokine pro-
files in the T2DM patients, the present studies have simply
identified associations and clearly additional randomized
studies are required to determine the cause and effect via
further examination of the role of endotoxin and the insu-
lin resistant state. However current data suggest that endo-
toxin may represent an important mediator for
inflammatory related metabolic risk.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
OA for the design, statistical analysis and drafting of the
manuscript; NA for the drafting and revising of the manu-
script; KA for the acquisition and interpretation of data;
NdS for performing the endotoxin assays; SS for the statis-
tical analysis and interpretation of data; PM and SK for the
concept, interpretation of data and intellectual input; AH
for the design and concept, manuscript development and
final revision of the paper.
Acknowledgements
The authors are grateful to staff at the Diabetes Center, King Abdul-Aziz 
University Hospital for the sample collection and Mr. Ahmed A. 
Bamakramah for the sample analysis and technical assistance. We would 
also like to thank the British Medical Association for providing funds to 
carry out these studies, as well as the Arden Medical Research Fund and 
the British Heart Foundation for supporting a fellowship for Dr Alison 
Harte.
References
1. Dandona P, Aljada A, Bandyopadhyay A: Inflammation: the link
between insulin resistance, obesity and diabetes.  Trends Immu-
nol 2004, 25:4-7.
2. Wellen KE, Hotamisligil GS: Inflammation, stress, and diabetes.
J Clin Invest 2005, 115:1111-1119.
3. Deeg MA: Basic approach to managing hyperglycemia for the
nonendocrinologist.  Am J Cardiol 2005, 96:37E-40E.
4. Sheehan MT: Current therapeutic options in type 2 diabetes
mellitus: a practical approach.  Clin Med Res 2003, 1:189-200.
5. Calabro P, Yeh ET: Obesity, inflammation, and vascular dis-
ease: the role of the adipose tissue as an endocrine organ.
Subcell Biochem 2007, 42:63-91.
6. Brix-Christensen V, Vestergaard C, Andersen SK, Krog J, Andersen
NT, Larsson A, Schmitz O, Tonnesen E: Evidence that acute
hyperinsulinaemia increases the cytokine content in essen-
tial organs after an endotoxin challenge in a porcine model.
Acta Anaesthesiol Scand 2005, 49:1429-1435.
7. Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, Wyn-
shaw-Boris A, Poli G, Olefsky J, Karin M: IKK-beta links inflamma-
tion to obesity-induced insulin resistance.  Nat Med 2005,
11:191-198.
8. Trayhurn P, Wood IS: Adipokines: inflammation and the pleio-
tropic role of white adipose tissue.  Br J Nutr 2004, 92:347-355.
9. Trayhurn P, Wood IS: Signalling role of adipose tissue: adipok-
ines and inflammation in obesity.  Biochem Soc Trans 2005,
33:1078-1081.
10. Kusminski CM, da Silva NF, Creely SJ, Fisher FM, Harte AL, Baker AR,
Kumar S, McTernan PG: The in vitro effects of resistin on the
innate immune signaling pathway in isolated human subcu-
taneous adipocytes.  J Clin Endocrinol Metab 2007, 92:270-276.Page 8 of 10
(page number not for citation purposes)
Cardiovascular Diabetology 2009, 8:20 http://www.cardiab.com/content/8/1/2011. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante
AW Jr: Obesity is associated with macrophage accumulation
in adipose tissue.  J Clin Invest 2003, 112:1796-1808.
12. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols
A, Ross JS, Tartaglia LA, Chen H: Chronic inflammation in fat
plays a crucial role in the development of obesity-related
insulin resistance.  J Clin Invest 2003, 112:1821-1830.
13. Stewart MW, Cirkel DT, Furuseth K, Donaldson J, Biswas N, Starkie
MG, Phenekos C, Hamann A: Effect of metformin plus roziglita-
zone compared with metformin alone on glycaemic control
in well-controlled Type 2 diabetes.  Diabet Med 2006,
23:1069-1078.
14. Weissman P, Goldstein BJ, Rosenstock J, Waterhouse B, Cobitz AR,
Wooddell MJ, Strow LJ: Effects of rosiglitazone added to sub-
maximal doses of metformin compared with dose escalation
of metformin in type 2 diabetes: the EMPIRE Study.  Curr Med
Res Opin 2005, 21:2029-2035.
15. Kim YW, Kim JY, Park YH, Park SY, Won KC, Choi KH, Huh JY,
Moon KH: Metformin restores leptin sensitivity in high-fat-fed
obese rats with leptin resistance.  Diabetes 2006, 55:716-724.
16. Chinetti G, Fruchart JC, Staels B: Peroxisome proliferator-acti-
vated receptors (PPARs): nuclear receptors at the cross-
roads between lipid metabolism and inflammation.  Inflamm
Res 2000, 49:497-505.
17. Buckingham RE: Thiazolidinediones: Pleiotropic drugs with
potent anti-inflammatory properties for tissue protection.
Hepatol Res 2005, 33:167-170.
18. Murdolo G, Smith U: The dysregulated adipose tissue: a con-
necting link between insulin resistance, type 2 diabetes mel-
litus and atherosclerosis.  Nutr Metab Cardiovasc Dis 2006,
16(Suppl 1):S35-38.
19. van Doorn M, Kemme M, Ouwens M, van Hoogdalem EJ, Jones R,
Romijn H, de Kam M, Schoemaker R, Burggraaf K, Cohen A: Evalu-
ation of proinflammatory cytokines and inflammation mark-
ers as biomarkers for the action of thiazolidinediones in
Type 2 diabetes mellitus patients and healthy volunteers.  Br
J Clin Pharmacol 2006, 62:391-402.
20. Charalambous BM, Stephens RC, Feavers IM, Montgomery HE: Role
of Bacterial Endotoxin in Chronic Heart Failure: the Gut of
the Matter.  Shock 2007, 28:15-23.
21. Creely SJ, McTernan PG, Kusminski CM, Fisher M, Da Silva NF,
Khanolkar M, Evans M, Harte AL, Kumar S: Lipopolysaccharide
activates an innate immune system response in human adi-
pose tissue in obesity and type 2 diabetes.  Am J Physiol Endocrinol
Metab 2007, 292:E740-747.
22. Brun P, Castagliuolo I, Leo VD, Buda A, Pinzani M, Palu G, Martines
D: Increased intestinal permeability in obese mice: new evi-
dence in the pathogenesis of nonalcoholic steatohepatitis.
Am J Physiol Gastrointest Liver Physiol 2007, 292:G518-525.
23. Galal O: Nutrition-related health patterns in the Middle East.
Asia Pac J Clin Nutr 2003, 12:337-343.
24. Hossain P, Kawar B, El Nahas M: Obesity and diabetes in the
developing world – a growing challenge.  N Engl J Med 2007,
356:213-215.
25. Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of
diabetes: estimates for the year 2000 and projections for
2030.  Diabetes Care 2004, 27:1047-1053.
26. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck
AM, Fava F, Tuohy KM, Chabo C, et al.: Metabolic endotoxemia
initiates obesity and insulin resistance.  Diabetes 2007,
56:1761-1772.
27. Backhed F, Manchester JK, Semenkovich CF, Gordon JI: Mecha-
nisms underlying the resistance to diet-induced obesity in
germ-free mice.  Proc Natl Acad Sci USA 2007, 104:979-984.
28. Westergaard H: Insulin modulates rat intestinal glucose trans-
port: effect of hypoinsulinemia and hyperinsulinemia.  Am J
Physiol 1989, 256:G911-918.
29. Krogh-Madsen R, Moller K, Dela F, Kronborg G, Jauffred S, Pedersen
BK: Effect of hyperglycemia and hyperinsulinemia on the
response of IL-6, TNF-alpha, and FFAs to low-dose endotox-
emia in humans.  Am J Physiol Endocrinol Metab 2004, 286:E766-772.
30. Yu WK, Li WQ, Li N, Li JS: Influence of acute hyperglycemia in
human sepsis on inflammatory cytokine and counterregula-
tory hormone concentrations.  World J Gastroenterol 2003,
9:1824-1827.
31. Byrne MM, Pluntke K, Wank U, Schirra J, Arnold R, Goke B, Katschin-
ski M: Inhibitory effects of hyperglycaemia on fed jejunal
motility: potential role of hyperinsulinaemia.  Eur J Clin Invest
1998, 28:72-78.
32. Cohen J: The detection and interpretation of endotoxaemia.
Intensive Care Med 2000, 26(Suppl 1):S51-56.
33. Guarner C, Soriano G, Tomas A, Bulbena O, Novella MT, Balanzo J,
Vilardell F, Mourelle M, Moncada S: Increased serum nitrite and
nitrate levels in patients with cirrhosis: relationship to endo-
toxemia.  Hepatology 1993, 18:1139-1143.
34. Mitaka C: Clinical laboratory differentiation of infectious ver-
sus non-infectious systemic inflammatory response syn-
drome.  Clin Chim Acta 2005, 351:17-29.
35. Kannel WB: Lipids, diabetes, and coronary heart disease:
insights from the Framingham Study.  Am Heart J 1985,
110:1100-1107.
36. Laakso M, Pyorala K: Adverse effects of obesity on lipid and
lipoprotein levels in insulin-dependent and non-insulin-
dependent diabetes.  Metabolism 1990, 39:117-122.
37. Hudgins LC, Parker TS, Levine DM, Gordon BR, Saal SD, Jiang XC,
Seidman CE, Tremaroli JD, Lai J, Rubin AL: A single intravenous
dose of endotoxin rapidly alters serum lipoproteins and lipid
transfer proteins in normal volunteers.  J Lipid Res 2003,
44:1489-1498.
38. Levine DM, Parker TS, Donnelly TM, Walsh A, Rubin AL: In vivo
protection against endotoxin by plasma high density lipopro-
tein.  Proc Natl Acad Sci USA 1993, 90:12040-12044.
39. Eggesbo JB, Hjermann I, Lund PK, Joo GB, Ovstebo R, Kierulf P: LPS-
induced release of IL-1 beta, IL-6, IL-8, TNF-alpha and
sCD14 in whole blood and PBMC from persons with high or
low levels of HDL-lipoprotein.  Cytokine 1994, 6:521-529.
40. Parker TS, Levine DM, Chang JC, Laxer J, Coffin CC, Rubin AL:
Reconstituted high-density lipoprotein neutralizes gram-
negative bacterial lipopolysaccharides in human whole
blood.  Infect Immun 1995, 63:253-258.
41. Wurfel MM, Hailman E, Wright SD: Soluble CD14 acts as a shut-
tle in the neutralization of lipopolysaccharide (LPS) by LPS-
binding protein and reconstituted high density lipoprotein.  J
Exp Med 1995, 181:1743-1754.
42. Wurfel MM, Kunitake ST, Lichenstein H, Kane JP, Wright SD:
Lipopolysaccharide (LPS)-binding protein is carried on lipo-
proteins and acts as a cofactor in the neutralization of LPS.
J Exp Med 1994, 180:1025-1035.
43. Feingold KR, Staprans I, Memon RA, Moser AH, Shigenaga JK, Doer-
rler W, Dinarello CA, Grunfeld C: Endotoxin rapidly induces
changes in lipid metabolism that produce hypertriglyceri-
demia: low doses stimulate hepatic triglyceride production
while high doses inhibit clearance.  J Lipid Res 1992,
33:1765-1776.
44. Fernandez-Real JM, Broch M, Richart C, Vendrell J, Lopez-Bermejo A,
Ricart W: CD14 monocyte receptor, involved in the inflam-
matory cascade, and insulin sensitivity.  J Clin Endocrinol Metab
2003, 88:1780-1784.
45. Eichbaum EB, Harris HW, Kane JP, Rapp JH: Chylomicrons can
inhibit endotoxin activity in vitro.  J Surg Res 1991, 51:413-416.
46. Harris HW, Grunfeld C, Feingold KR, Read TE, Kane JP, Jones AL,
Eichbaum EB, Bland GF, Rapp JH: Chylomicrons alter the fate of
endotoxin, decreasing tumor necrosis factor release and
preventing death.  J Clin Invest 1993, 91:1028-1034.
47. Rosenstock J, Rood J, Cobitz A, Biswas N, Chou H, Garber A: Initial
treatment with rosiglitazone/metformin fixed-dose combi-
nation therapy compared with monotherapy with either ros-
iglitazone or metformin in patients with uncontrolled type 2
diabetes.  Diabetes Obes Metab 2006, 8:650-660.
48. Bornstein SR, Licinio J, Tauchnitz R, Engelmann L, Negrao AB, Gold
P, Chrousos GP: Plasma leptin levels are increased in survivors
of acute sepsis: associated loss of diurnal rhythm, in cortisol
and leptin secretion.  J Clin Endocrinol Metab 1998, 83:280-283.
49. Bornstein SR, Preas HL, Chrousos GP, Suffredini AF: Circulating
leptin levels during acute experimental endotoxemia and
antiinflammatory therapy in humans.  J Infect Dis 1998,
178:887-890.
50. Granowitz EV, Porat R, Dinarello CA: Circulating leptin during
experimental endotoxemia in humans.  J Infect Dis 1999,
179:1313-1314.Page 9 of 10
(page number not for citation purposes)
Cardiovascular Diabetology 2009, 8:20 http://www.cardiab.com/content/8/1/20Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
51. Berkowitz DE, Brown D, Lee KM, Emala C, Palmer D, An Y, Breslow
M: Endotoxin-induced alteration in the expression of leptin
and beta3-adrenergic receptor in adipose tissue.  Am J Physiol
1998, 274:E992-997.
52. Grunfeld C, Zhao C, Fuller J, Pollack A, Moser A, Friedman J, Feingold
KR: Endotoxin and cytokines induce expression of leptin, the
ob gene product, in hamsters.  J Clin Invest 1996, 97:2152-2157.
53. Wu J, Lei MX, Chen HL, Sun ZX: [Effects of rosiglitazone on
serum leptin and insulin resistance in patients with Type 2
diabetes].  Zhong Nan Da Xue Xue Bao Yi Xue Ban 2004, 29:623-626.
54. Lu H, Raptis M, Black E, Stan M, Amar S, Graves DT: Influence of
diabetes on the exacerbation of an inflammatory response in
cardiovascular tissue.  Endocrinology 2004, 145:4934-4939.Page 10 of 10
(page number not for citation purposes)
